---
title: "argenx SE Shareholders Approve Remuneration Policy at Extraordinary Meeting"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/266442200.md"
description: "Argenx SE announced the approval of its remuneration policy at an Extraordinary General Meeting on November 18, 2025, with 95.67% majority support. The policy's approval highlights strong shareholder backing and may impact governance and stakeholder relations. The latest analyst rating for ARGX stock is a Buy with a $1124.00 price target. TipRanks’ AI Analyst rates ARGX as Outperform due to strong financial performance and bullish technical indicators, despite high valuation and cash flow challenges."
datetime: "2025-11-18T22:31:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/266442200.md)
  - [en](https://longbridge.com/en/news/266442200.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/266442200.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/266442200.md) | [English](https://longbridge.com/en/news/266442200.md)


# argenx SE Shareholders Approve Remuneration Policy at Extraordinary Meeting

### Meet Your ETF AI Analyst

-   Discover how TipRanks' _ETF_ AI Analyst can help you make smarter investment decisions
-   Explore ETFs TipRanks' users love and see what insights the **_ETF_ AI Analyst** reveals about the ones you follow.

The latest announcement is out from Argenx Se ( (ARGX) ).

On November 18, 2025, argenx SE announced the approval of its remuneration policy during the Extraordinary General Meeting of shareholders. The policy was approved by a 95.67% majority, with 91.1% of share capital represented, highlighting strong shareholder support and potentially impacting the company’s governance and stakeholder relations.

The most recent analyst rating on (ARGX) stock is a Buy with a $1124.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.

**Spark’s Take on ARGX Stock**

According to Spark, TipRanks’ AI Analyst, ARGX is a Outperform.

Argenx Se’s strong financial performance and bullish technical indicators are the primary drivers of its high stock score. The company’s robust revenue growth and strategic advancements in its pipeline are significant positives. However, the high valuation and operational challenges in cash flow generation slightly temper the overall score.

To see Spark’s full report on ARGX stock, click here.

**More about Argenx Se**

argenx is a global immunology company focused on developing and commercializing novel antibody-based medicines for severe autoimmune diseases. Through its Immunology Innovation Program, argenx collaborates with academic researchers to advance its portfolio, including the first approved neonatal Fc receptor (FcRn) blocker.

**Average Trading Volume:** 364,155

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $55.65B

### 相關股票

- [Argenx (ARGX.US)](https://longbridge.com/zh-HK/quote/ARGX.US.md)

## 相關資訊與研究

- [Nilsine Partners LLC Takes $3.07 Million Position in argenex SE $ARGX](https://longbridge.com/zh-HK/news/281354774.md)
- [UBS Keeps Their Hold Rating on Argenx Se (ARGX)](https://longbridge.com/zh-HK/news/281327621.md)
- [What Happens Next After the QQQ ETF’s 3% Single-Day Move? Here’s What History Tells Us.](https://longbridge.com/zh-HK/news/281552388.md)
- [The AI Revolution and The 90s Internet Boom](https://longbridge.com/zh-HK/news/281005956.md)
- [TCS Rewires Enterprise Tech With AI](https://longbridge.com/zh-HK/news/280993412.md)